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T lymphocytesStudies suggest that inﬂammation is involved in the neurodegenerative cascade of dementias. Immunological
mechanisms may be part of the pathophysiological process in frontotemporal dementia (FTD), but up till now
only vague evidence of suchmechanismshas been presented. The B7- CD28/CTLA-4 pathway is an important im-
munological signaling pathway involved inmodulation of T cell activation. The aim of this study was to compare
the expression of molecules associated with co-stimulatory signaling in peripheral blood mononuclear cells
(PBMC) of FTD to Alzheimer disease (AD) and control groups. Our results conﬁrm the previous demonstrated in-
creased expression of CD80 in CD14+ Alzheimer patients T cells but show, for the ﬁrst time, a reduction in the
expression of CTLA-4 in CD4+ FTD cells. As CTLA-4 is the most potent negative regulators of T-cell activation
we speculated that peripheral T lymphocytes in FTD are more activated and this could be involved in the
neurodegeneration observed in this dementia.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Frontotemporal dementia (FTD) is an umbrella term that groups sev-
eral different neurodegenerative diseases characterized by predominant
destruction of the frontal and temporal lobe. It is a clinical syndrome
marked by progressive changes in personality and interpersonal conduct
(behavioural-variant frontotemporal dementia – bvFTD), or language
(progressive nonﬂuent aphasia, PNAF, or semantic dementia, SD). Pa-
tients with bvFTD are disinhibited, socially inappropriate, and show a
lack of insight and concern (McKhann et al., 2001). Other patients pre-
dominantly present with apathy, inertia, and loss of volition (Snowden
et al., 2001). Expressive language is the hallmark of PNAF patients whilst
deterioration of verbal and non-verbal conceptual knowledge is charac-
teristic of SD. In clinical practice FTD is commonly misdiagnosed as
Alzheimer disease (Hodges and Patterson, 2007).senting cell; bvFTD, behavioural-
; CNS, central nervous system;
CTRL, control patients; FTD,
yte antigen complex; MHC,
ate examination; PBMC, periph-
aphasia; SD, semantic dementia;
55 31 34099134.
ghts reserved.The ability to discriminate between self and non self is one themost
fundamentally important aspects of the immune system. This ability is
achieved by complex regulation mechanisms involving immune cells
andmolecules including cytokines and chemokines.When this complex
regulation process is altered the immune system's destructive effects
become evident. Cytokines and their receptors are expressed physiolog-
ically in central nervous system (CNS) cells and are important for devel-
opment and function of the brain (Schmitz and Chew, 2008). The
detrimental effect of immune system on CNS is seen inmany conditions
such asmultiple sclerosis. There is considerable evidence to suggest that
an inﬂammatory response may be involved in the neurodegenerative
cascade in Alzheimer disease (AD) and other dementias as well
(Eikelenboom et al., 2010; McGeer and McGeer, 2010).
Onemechanism designed tomaintain the ﬁdelity of the immune re-
sponse is the two-signal concept of lymphocyte activation: an antigen-
speciﬁc signal via the T cell receptor (Signal 1) and a co-stimulatory
signal (Signal 2) that is provided by soluble factors or cell-surface mol-
ecules on the antigen presenting cell (APC) (Bretscher, 1999).
Signal 1 is provided by interaction of the antigen with the major-
histocompatibility-complex (MHC) and T-cell-receptor (TCR). In the
absence of signal 2,lymphocytes are usually rendered anergic, but when
this signal is very strong lymphocyte activation can occur. Signal 2 is
delivered to T cells by co-stimulatory cell surface molecules expressed
on antigen-presenting cells (APC) (Bretscher, 1999). The second signal
can have a stimulatory or inhibitory nature. The balance of both signals
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T cell tolerance, whereas a positive signal promotes T cell activation
(Sharpe and Freeman, 2002). The main co-stimulatory signal is the
B7-1/B7-2-CD28/CTLA-4 pathway. B7-1(CD80) and B7-2 (CD86) lo-
cated on the surface of APC have speciﬁcity for the stimulatory recep-
tor (CD28) or the inhibitory receptor CTLA-4 (CD152). Signalling
through CD28 promotes cytokine production (IL-2 and TNF-α), in-
creases CD40L and enhances T cell survival by activation of NF-κβ
and upregulation of Bcl-XL (Boise et al., 1995; Sperling et al., 1996;
Thompson et al., 1989). The opposing outcome is observed with
CTLA-4 engagement which inhibits IL-2 synthesis and causes a T
cell cycle arrest. CTLA-4 has a crucial role in regulating peripheral T
cell tolerance (Greenwald et al., 2002; Oosterwegel et al., 1999).
To our knowledge, there are no studies evaluating the pathway
B7-CD28/CTLA-4 pathway in AD or FTD. Therefore, the aim of this
study is to evaluate the expression of molecules associated with co-
stimulatory signalling in peripheral blood mononuclear cells (PBMC)
of FTD patients compared to Alzheimer disease (AD) patients.
2. Subjects and methods
Patients were selected from the outpatient clinic of Jenny de
Andrade Faria Geriatric Institute of Universidade de Minas Gerais
(UFMG)–Brazil, which is the elderly reference centre in the state
of Minas Gerais. The Ethics Committee of the federal university,
UFMG, approved the study and all procedures were according to
the local board of regulation. All patients were evaluated using the
institute's full standard1 evaluation protocol. They were also evaluat-
ed by at least two physicians. Neuropsychology and phonological
specialists evaluated the patients when necessary. To be enrolled,
study subjects fulﬁlled the standard clinical criteria for probable or
possible AD (McKhann et al., 1984), or FTD (Neary et al., 1998). Se-
vere demented patients (clinical dementia rate equals to 3 or with
impairment in basic activity of daily life) were not allowed to be en-
rolled. Patients who performed the same protocol evaluation, includ-
ing cognitive tests, without any signiﬁcant ﬁnding or depression,
were enrolled in the control group. Besides diagnosis criteria already
mentioned, all patients fulﬁlled exclusion criteria, therefore they did
not have the following conditions: inﬂammatory disease; acute con-
ditions at the time of blood collection; any decompensated chronic
disease (including diabetes mellitus, chronic pulmonary disease) or
any other neuropsychiatric disorder.
Bloodwas collected from patients and peripheral bloodmononucle-
ar cells (PBMC) were obtained using a Ficoll/Hypaque gradient. Flow
cytometric analysis was performed as described by Torres et al., 2005
(Torres et al., 2005). PBMCwere cultured in RPMI (Roswell ParkMemo-
rial Institute-1640) supplementedwith 10% foetal bovine serum, 200 μL
de L-glutamine and 1% penicillin-streptomicin. This procedure was
undertaken to increase costimulatory surface marker expression. Cells
were then stained with antibody solutions. The antibodies used for
staining of antigens expressed on the cell surface were anti-CD19-Cy,
anti-CD4-FITC, anti-CD14-FITC, anti-CD80-PE, anti-CD28-PE and anti-
CTLA-4-Cy5. Additionally, FITC, PE and Cy5-labeled immunoglobulin
isotype control antibodies were included in all experiments. Next, the
preparationswerewashed and ﬁxedwith 2% formaldehyde. The stained
cells were acquired and analysed using a ﬂow cytometer (Guava/GE).
Leucocytes were analysed for their surface marker frequencies using
the Cytosoft program. Statistical analyses were performed using the
software GraphPad Prism, version 6.0c, for Mac, March 2013. The
nonparametric Kruskal–Wallis one-way analysis test of variance follow-
ing Dunn's Multiple Comparison test was used for comparing the1 Standard protocol includes mainly: medical review of physiological system, cognitive
tests (MEEM, verbal ﬂuency, clock-drawing, Frontal Assessment Battery, delayed recall
subtest of CERAD or pictures), clinical dementia rate, depression scales, neuropsychiatric
inventory, functional evaluation, gait and equilibrium tests, lab exams and imaging.distribution of the three unmatched groups (FTD, AD and control
group). When comparison was made between the two groups (FTD
and AD) aMannWhitney test was used. The frequency of gender distri-
bution was tested among the three groups using Chi-squared test. In all
cases two-tail P-values less than 0.05 were taken to be signiﬁcant. A
normality test (Shapiro–Wilk normality test and D'Agostino-Pearson
omnibus test) was also used to support the use of non-parametric
test. All graphs were plotted using the traditional Tukey box-and-
whisker. The top and bottom of the box are always the 25th and 75th
percentiles plot and the line inside the box is the median. Results,
along the text, are presented as median (25th-75th percentile). Any
data beyond the whiskers (outliers) are shown as points (as shown in
Fig. 2B).
3. Results
A total of 46 patients were included in this study. They were di-
vided into three groups: 27 AD, 10FTD and 9 control patients. The
frontotemporal dementia group was composed of: 7 patients with
behaviour variant frontotemporal dementia (bvFTD), 2 patients
with progressive non-ﬂuent aphasia (PNAF), and 1 patient with se-
mantic dementia (SD). Only mild to moderate demented patients
were enrolled in this study. FTD group was statistically different
from both groups when age was analysed by Kruskal–Wallis one-
way analysis of variance followed by Dunn's Multiple Comparison
test (p b 0.0001). Mini Mental State Examination (MMSE) was dif-
ferent when AD and control group were analysed, but there was no
statistical difference when AD and FTD were analysed.
The ﬁrst step performed in order to study co-stimulatory receptor-
ligand pair in T cell response measured the surface expression of B7-1
(CD80, which is the ligant for CD28) in CD14+ (monocytes) and in
CD19+(lymphocyte B) cells (Fig. 1)which is the ligand for CD28. Its ex-
pression is inducible in antigen-presenting cells or dendritic cells upon
stimulation. As shown in Fig. 1, AD patients presented a statistically sig-
niﬁcant increase in CD80 expression in CD14+ when compared to con-
trol group, but not when compared to FTD. No differences were found
between the three groups in relation to CD19+cells. In CD14+ cells
the median expression of CD80 was 2.25 (1.55–6.48) in CTRL group,
9.00 ± 2.27 in AD and 3.41 ± 1.19 in FTD; p = 0.023. For CD19+
cells the median expression of CD80 was 7.01 (3.33–10.00) in CTRL,
7.70 (5.42–10.36) in AD and 6.70 (3.63–33.96) in FTD; p = 0.792.
Afterwards, the expression of stimulatory receptor (CD28) and the
inhibitory receptor CTLA-4 (CD152) were also measured to complete
that pathway. There was no difference in the percentage of CD4+ cells
expressing CD28 among the three groups. In those cells the median ex-
pression of CD28was 92.00 (91.00–96.00) in CTRL, 88.00 (83.00–92.00)
in AD and 92.00 (83.00–94.00) in FTD; p = 0.465.
When the inhibitory stimulus of B7-CD28/CTLA-4 pathway was
evaluated, a clear alteration was observed. As shown in Fig. 2B, FTD
group shows a very signiﬁcant reduction in the expression of this recep-
tor (p = 0.006) in CD4+. Median expression of CTLA-4 in CD4+ was
3.67 (1.27–8.84) in CTRL, 1.00 (0.63–2.80) in AD and 0.45 (0.24–0.55)
in FTD; p = 0.006.
Peripheral expression of other immune molecules, apart from co-
stimulatorysignalling, is also altered in FTD. Previous work (publication
pending) performed by our group have already shown that T cells from
FTD patients have increased expression of tumour necrosis factor alpha
and other cytokines. Both results are aligned with the idea that FTD T
cells are more activated. Besides these alterations, additional evidence
that there is impaired immune signals in CD14+ cells from FTD patients
were observed. When IL-1α or HLA-DR expression in CD14+ mono-
cytes were analyzed, a downward trend in FTD was observed (Fig. 3).
In those cells the median expression of IL-1α was 93.00 (29–96) in
CTRL, 94.00 (38.00–97.00) in AD and 34.00 (6.20–79.00) in FTD; p =
0.07. Median expression of HLA-DR was 74.03 (26.48–87.88) in CTRL,
65.70 (27.62–84.75) in AD and 19.84 (4.67–37.44) in FTD; p = 0.09.
Fig. 1. CD80 expression. Frequency of B7-1 expression in CD14+ (A) and CD19+ cells (B)
of patientswith frontotemporal dementia (FTD), Alzheimer (AD) and control (CTRL). Data
is presented as tradional Tukey box-and-whisker plot. The nonparametric test Kruskal–
Wallis one-way analysis of variance was used to compare the distribution of the three
unmatched groups followed by Dunn'sMultiple comparison test. P b 0.05was considered
statistically different. The * sign means that p b 0.05.
Fig. 2. Receptors of B7-CD28/CTLA-4 pathway. CD28 and CTLA4 expression in CD4++ cells
of patients with frontotemporal dementia (FTD), Alzheimer (AD) and control group
(CTRL). Data is presented as traditional Tukey box-and-whisker plot. Any data beyond
the whiskers (outliers) are shown as points. The nonparametric test Kruskal–Wallis
one-way analysis of variance was used for comparing the distribution of the three
unmatched groups and p b 0.05 was considered statistically different. The ** sign means
that p b 0.01.
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test), a reduction in IL-1α (p = 0.025) and HLA-DR (p = 0.039) was
detected.
4. Discussion
Neurodegenerative diseases are characterized by signiﬁcant neuro-
nal loss. Despite the progress made in the last decade in understanding
the molecular mechanism that causes neuronal loss in FTD, it is still a
ﬁeld in its infancy. Immune molecules such as cytokines are involved
in neuronal death causing dementia processes. The literature clearly
shows that peripheral T cells are activated in AD (Liu et al., 2010;
Schindowski et al., 2007; Town et al., 2005).
When B7-1 (CD80) binds to its stimulatory receptor (CD28), cyto-
kine production (IL-2 and TNF-α) is promoted (Sperling et al., 1996).
B7-2 (CD86) is also a ligand for CD28, which is inducible later in the im-
mune response (Goronzy and Weyand, 2008). The B7-1 ⁄ B7-2 ⁄ CD28
pathway has been shown to constitute the primary and strongest
costimulatory signal delivered by APCs to amplify Tcell activation
(Green et al., 1994). Meta-analysis reports signiﬁcantly higher concen-
trations of the proinﬂammatory cytokines IL-6, TNF-α, IL-1β, IL-12,
and IL-18 in the peripheral blood of AD subjects compared with control
subjects (Swardfager et al., 2010).
A recent work from Xue et al. (2009) shows an increase in HLA-DR
and CD80 molecules from Alzheimer patients' blood. The increase in
CD80 expression in CD4+ observed in our study is in agreement with
this work and it also supports the idea that T cells are involved in ADpathology. AD is the main differential diagnosis of FTD in clinical prac-
tice. When HLA-DR expression was compared in these two groups a re-
duction in its expression was observed in FTD. HLA-DR allows antigen
presentation to T cells and is crucial for the initiation of the immune cas-
cade (Unanue et al., 1984). CD14+ cells seem to be less activated in FTD
when compared to AD. This idea is supported by the reduction of IL-1α
expression, as shown in Fig. 3B. The reduction of HLA-DR and IL-1α in
FTD highlight the contrast between these two conditions regarding
their immune proﬁle.
CD 28 is also expressed not only in CD4+ T cells (Fig. 2) but in
CD8+ T cells as well. Normally during aging, loss of CD28 is expected
to occur in T cells, mainly in CD8+ T cells, and this process may be accel-
erated in susceptible individuals. Onemechanism to explain this is based
on the capability of tumour necrosis factor (TNF) to down regulate CD28
molecules (Bryl et al., 2001). Although the FTD group is slightly younger
than the other groups, there is no difference in CD28 expression. As we
analysed CD28 expression in CD4+Tcells, aging is not expected to inter-
fere in this results.
In addition to the effect on cytokine production previously men-
tioned, CD28 signalling also provides a potent synergistic signal for tran-
scription factors such as nuclear factor-κβ(NF-κβ), nuclear factor of
activated T cells (NFAT), and activator protein-1 (AP1) (Goronzy and
Weyand, 2008). CTLA-4 has an inhibitory effect in this pathway and
its signal mediates cell death (Kane et al., 2002; Rincón and Flavell,
1994).
When CTLA-4 expression was analysed a striking reduction was ob-
served in FTD patients compared to AD or control groups. This reduction
Fig. 3. IL1-α and HLA-DR expression in CD14+ cells of patients with frontotemporal de-
mentia (FTD), Alzheimer (AD) and control group (CTRL). Data is presented as traditional
Tukey box-and-whisker plot. The nonparametric test Kruskal–Wallis one-way analysis
of variance was used for comparing the distribution of the three unmatched groups and
p b 0.05 was considered statistically different.
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effects promoted by CD80 or CD86. The mechanism responsible for the
regulation of CD28 and CTLA-4 expression vary considerably. CD28 is
constitutively expressed on CD4+ T cells, on the other hand, CTLA-4
expression is induced in response to TCR ligation and the majority is lo-
calized in several intracellular compartments. Minor differences in its
expression can have potentially detrimental effects, such as develop-
ment of autoimmune disease or lymphoproliferative diseases (Goronzy
and Weyand, 2008; Rudd et al., 2009).
Peripheral cytokines can promote signaling inside CNS (Fil et al.,
2011). In the Framingham study it was observed that higher levels of
production of the inﬂammatory cytokines IL-1 or TNF-αby PBMC was
associated with an increased risk for developing AD (Tan et al., 2007).Table 1
Demographic data from patients.
Group Name Control
(n = 9)
Alzheimer
(n = 27)
Frontotemporal dementia
(n = 10)
p value
Age Mean
(± SD)
76.9 (7.76) 78.0 (6.01)* 65.6 (5.7)** b0.0001
Sex (♂:♀) 2:7 9:18 5:5 0.43†
MMSE Value
(± SD)
25.8 (2.61) 13.5 (4.34)*** 17.7 (10.48) b0.05
MMSE = mini-mental state examination. P valueswere calculated using Kruskal–Wallis test
followed by Dunn's Multiple Comparison test; *ADvs Control P b 0.05 in Dunn's Multiple
Comparison test; **FTD vs Control or ADP b 0.0001in Dunn's Multiple Comparison test;
†X2-test; ***AD vs ControlP b 0.0004 in Dunn's Multiple Comparison test.It is obvious that peripheral alterations may not reﬂect exactly what
happens inside brain and it is therefore necessary to take this into con-
sideration when analysing our ﬁndings. Previous work has already
demonstrated that PBMC can beused as a probe to study psychiatric dis-
orders (Cosentino et al., 2009; Gatta et al., 2009; Gladkevich et al., 2004;
Magaki et al., 2007; Torres et al., 2009). It is also important to highlight
that cytometric analysis of PBMC is a minimally invasive procedure,
easy to replicate or perform in clinical settings.
CTLA-4 is considered one of the most potent negative regula-
tors of T cell activation. CTLA-4 deﬁcient mice develop a severe
lymphoproliferative disorder and die within few weeks after birth
(Waterhouse et al., 1995). T cell co-stimulation signalling has progressed
from bench to bedside. Inhibition of CD28 pathway is an important strat-
egy to block rejection of transplants or control autoimmune disease
(Bour-Jordan et al., 2011; Driessens et al., 2009). There are studies using
Abatacept (CTLA-4-immunoglobulin) to treat rheumatoid arthritis, sys-
temic lupus erythematosus and multiple sclerosis (Linsley and Nadler,
2009). Although modulation of T cell co-stimulation is already in clinical
use and its inﬂuence in immune response is well recognized, there are no
reports about the role of B7-CD28/CTLA-4 pathway in primary degenera-
tive dementias including Alzheimer disease, frontotemporal dementia
and others.
As expected, FTD group was younger than AD. Although AD is the
commonest dementia in all ages, it is more prevalent in older people,
whilst FTD is just the opposite. In clinical practice, the differential diag-
nosis in any age is not easy and a biomarker could be very useful. As
there are no signiﬁcant alterations in cytokine expression between
these age groups (Faria et al., 2008), the authors believe that the two
groups are comparable and do not interfere with the study conclusion.
Immunological parameters change throughout the course of neurode-
generative disease. In order to make the groups more comparable, no
clinical dementia rate stage 3 patients were enrolled. The results
presented in Table 1 reﬂected the clinical picture found in both groups
since the higher MMSE scores were a good indication of early stage
FTD and MMSE was signiﬁcantly altered in Alzheimer disease.
5. Conclusion
This work clearly shows that CTLA-4 expression in CD4+ T cells from
frontotemporal dementia patients' blood is reduced when compared to
Alzheimer and control groups. The difference in HLA-DR and IL-1α ex-
pression in CD14+in FTD patients compared to AD patients supports
the idea that the role of immune system in FTD is different from AD
and needs further investigation. As far as we know, this is the ﬁrst
study to demonstrate an alteration in B7-CD28/CTLA-4 in primary de-
generative dementias, particularly FTD. Although we cannot clarify the
importance of molecules associated with co-stimulatory signaling in
FTD neurodegenerative processes, these results clearly highlight a new
path to be investigated.
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